Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Ataxia associated with anti-glutamic acid decarboxylase antibodies

https://doi.org/10.14412/2074-2711-2020-5-66-70

Abstract

Anti-glutamic acid decarboxylase (GAD) antibody-associated ataxia is a rarely diagnosed but potentially curable disease associated with autoimmune damage to and death of Purkinje cells in the cerebellar cortex. In Russia, the authors have provided for the first time descriptions of three own observations of this disease, which had a number of clinical features, such as slow progression, mild ataxia, stroke-like episodes with stem symptoms, concomitant gluten sensitivity, onset of ataxia after hepatitis C with cerebellar hemiataxia and hemiatrophy. In the all patients, the diagnosis was verified based on the determination of high anti-GAD antibody titers in serum and cerebrospinal fluid. All the patients lacked intrathecal synthesis of oligoclonal antibodies; protein levels and cytosis were normal. Pulse therapy with methylprednisolone at a total dose of 3–5 g led to a slight reduction in ataxia in one case (a female patient with subacute onset of the disease); the treatment was ineffective in two other cases (patients with a primary chronic course). The paper analyzes the literature covering the pathogenesis and clinical presentations of this type of ataxia, and difficulties in its diagnosis and treatment.

About the Authors

E. P. Nuzhnyi
Research Center of Neurology
Russian Federation

Evgeny P. Nuzhnyi

80, Volokolamskoe Shosse, Moscow 125367




M. Yu. Krasnov
Research Center of Neurology
Russian Federation

80, Volokolamskoe Shosse, Moscow 125367



D. R. Akhmadullina
Research Center of Neurology
Russian Federation

80, Volokolamskoe Shosse, Moscow 125367



A. A. Abramova
Research Center of Neurology
Russian Federation

80, Volokolamskoe Shosse, Moscow 125367



E. Yu. Fedotova
Research Center of Neurology
Russian Federation

80, Volokolamskoe Shosse, Moscow 125367



S. N. Illarioshkin
Research Center of Neurology
Russian Federation

80, Volokolamskoe Shosse, Moscow 125367



References

1. Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015 Nov 10;2:14. doi: 10.1186/s40673-015-0034-y. eCollection 2015.

2. Hadjivassiliou M, Boscolo S, Tongiorgi E, et al. Cerebellar ataxia as a possible organ specific autoimmune disease. Movement Disord. 2008 Jul 30;23(10):1370-7. doi: 10.1002/mds.22129

3. Baizabal-Carvallo JF. The neurological syndromes associated with glutamic acid decarboxylase antibodies. J Autoimmun. 2019 Jul;101:35-47. doi: 10.1016/j.jaut.2019.04.007. Epub 2019 Apr 15.

4. Isaeva NV, Prokopenko SV, Rodikov MV, et al. Сlinical features of stiff-person syndrome. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;119(6):96-100. doi: 10.17116/jnevro201911906196 (In Russ.).

5. Krasnov MYu, Pavlov EV, Ershova MV, et al. The range of neurological syndromes associated with glutamic acid decarboxylase antibodies. Annaly klinicheskoy i experimental'noy nevrologii. 2015;9(4):37-41 (In Russ.).

6. Serdjuk AV, Kovrazhkina EA. A case report of stiff-person syndrome with myoclonus and dysautonomia. Consilium Medicum. 2017;19(9):65-8. doi: 10.26442/2075-1753_19.9.65-68 (In Russ.).

7. Sorokina EA, El'chaninov DV, Plotnikova AA, et al. Stiff-person syndrome. Nevrologicheskii zhurnal. 2018;23(4):195-200. doi: 10.18821/1560-9545-2018-23-4-195-200 (In Russ.).

8. Zinov'eva OE, Katushkina JeA, Mozolevskij YuV, et al. Stiff-man syndrome: the aspects regarding its pathogenesis and treatment. Nevrologicheskii zhurnal. 2009;14(1):11-7 (In Russ.).

9. Yakhno NN, Golubeva VV, Mozolevskij YuV, et al. Stiff-person syndrome with oculomotor and cerebellar disturbances. Annaly klinicheskoy i experimental'noy nevrologii. 2007;1(4):15-22 (In Russ.).

10. Matsumoto S, Kusuhara T, Nakajima, et al. Acute attacks and brain stem signs in a patient with glutamic acid decarboxylase autoantibodies. J Neurol Neurosurg Psychiatry. 2002 Sep;73(3):345-6. doi: 10.1136/jnnp.73.3.345

11. Munoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e696. doi: 10.1212/NXI.0000000000000696

12. Hadjivassiliou M, Aeschlimann D, Grunewald RA, et al. GAD antibody associated neurological illness and its relationship to gluten sensitivity. Acta Neurol Scand. 2011 Mar;123(3):175-80. doi: 10.1111/j.1600-0404.2010.01356.x

13. Nanri K, Okuma M, Sato S, et al. Prevalence of autoantibodies and the efficacy of immunotherapy for autoimmune cerebellar ataxia. Intern Med. 2016;55(5):449-54. doi: 10.2169/internalmedicine.55.5156. Epub 2016 Mar 1.

14. Wiels W, Guisset F, Vandervorst F, et al. Rapidly progressive cerebellar hemiataxia with high levels of GAD65 reactive antibodies. Mov Disord Clin Pract. 2017 Jun 1;4(4):632-4. doi: 10.1002/mdc3.12504. eCollection Jul-Aug 2017.

15. Awad A, Stuve O, Mayo M, et al. Anti-glutamic acid decarboxylase antibody-associated ataxia as an extrahepatic autoimmune manifestation of hepatitis C infection: a case report. Case Rep Neurol Med. 2011;2011:975152. doi: 10.1155/2011/975152. Epub 2011 Jul 10.

16. Navarta LM, Espul CA, Acosta-Rivero N. High prevalence of a variety of autoantibodies in a population of hepatitis C virus-infected individuals. APMIS. 2018 Jun;126(6):515-22. doi: 10.1111/apm.12850

17. Fujioka T, Honda M, Yoshizaki T, et al. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C. Intern Med. 2010;49(18):1987-90. doi: 10.2169/internalmedicine.49.3831. Epub 2010 Sep 15.

18. Shiba T, Morino Y, Tagawa K, et al. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract. 1995 Dec;30(3):237-41. doi: 10.1016/0168-8227(95)01188-9

19. Baizabal-Carvallo JF, Alonso-Juarez M. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide. J Neuroimmunol. 2018 Apr 15;317:5-7. doi: 10.1016/j.jneuroim.2018.01.013. Epub 2018 Feb 3.


Review

Views: 510


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)